Chris Chen, WuXi Biologics CEO (Anthony Kwan/Bloomberg via Getty Images)
March 18, 2021 09:37 AM EDT
Manufacturing

Pfiz­er lays down its hand on Chi­nese biosims, of­fload­ing its 3-year-old plant to WuXi Bi­o­log­ics as com­pe­ti­tion grows

Kyle Blankenship

Pfiz­er is in down­siz­ing mode af­ter a hefty spin­off of its Up­john gener­ics unit and a full-scale piv­ot to­ward brand­ed meds. That move left Pfiz­er’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The brain is Eli Lil­ly's next tar­get for its obe­si­ty meds

Lil­ly’s oral SERD makes strides in breast can­cer with Phase 3 da­ta

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Gene edit­ing com­pa­nies seek safer, less gru­el­ing con­di­tion­ing meth­ods for blood stem cell ther­a­pies

Ace­lyrin says good­bye to the drug that got it a $540M IPO in 2023

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times